GlassScriptPhysician profile
Mitchell J Spirt
NPI 1568476471
$5,191.53
in general payments reported to CMS, 2019-2025
34 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $662 · 2021: $854 · 2022: $731 · 2023: $331 · 2024: $787 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087 · Education: $55.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.49 |
| Education | $55.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,009.24 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $638.28 | 2019-2025 | Trulance, Relistor |
| Pfizer INC. | $604.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $311.14 | 2019-2023 | Dificid |
| Ardelyx, INC. | $302.72 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $297.73 | 2020-2025 | Tremfya, Stelara |
| Celltrion USA INC. | $263.63 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $231.00 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $206.48 | 2020-2023 | Rebyota, Cimzia |
| Qol Medical, LLC | $128.70 | 2019-2020 | |
| Redhill Biopharma INC. | $110.33 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $98.65 | 2019-2022 | |
| Amgen INC. | $87.71 | 2019-2022 | |
| Novo Nordisk INC | $84.30 | 2023-2025 | Wegovy |
| Capsovision, INC. | $79.53 | 2024-2025 | Capsocam Plus |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $73.79 | 2021-2024 | Eohilia |
| Regeneron Healthcare Solutions, INC. | $68.37 | 2022 | |
| Nestle Healthcare Nutrition INC. | $66.09 | 2020-2023 | |
| Celgene Corporation | $56.60 | 2021 | |
| Exact Sciences Corporation | $52.53 | 2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $43.67 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $42.73 | 2023 | Gimoti |
| Allergan, INC. | $40.04 | 2019-2020 | |
| Ucb, INC. | $39.57 | 2019 | |
| Lilly USA, LLC | $34.77 | 2024 | Omvoh |
| Shionogi INC | $33.85 | 2019 | |
| Organon LLC | $32.55 | 2024 | |
| Aimmune Therapeutics, INC. | $29.15 | 2025 | Vowst |
| Alfasigma USA, INC. | $22.79 | 2020 | |
| Idorsia Pharmaceuticals US INC | $21.97 | 2022 | |
| Daiichi Sankyo INC. | $21.37 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $21.35 | 2023 | |
| Concordia Pharmaceuticals INC. | $20.58 | 2019 | |
| Currax Pharmaceuticals LLC | $16.00 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Spirt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.